We are pleased to confirm an agreement with emerging UK drug turnaround biotech Ignota Labs to collaborate on the exchange of data from Inaphaea's Biobank to generate insights, co-develop new assets, and explore joint business opportunities, including grant funding.

Ignota Labs will analyse data from Inaphaea's Biobank to develop in-silico models. These models will help identify new oncology assets, with plans to co-develop them through Inaphaea's tCRO® services and Ignota's platform.

Read the full RNS here.